eRADicAte: A Study of Radium-223 with Abiraterone Acetate in Castration-Resistant Prostate Cancer with Symptomatic Bone Metastases - Neal Shore

June 28, 2016

Neal Shore, MD. presents the eRADicAte study, an open label phase two clinical trial of radium-223 with concurrent administration of abiraterone acetate plus prednisone in castration-resistant prostate cancer (CRPC) subjects with symptomatic bone metastases without visceral metastases.  These results were first presented at the AUA 2016.  

Potential synergy exists in combining radium-223 and abiraterone acetate.  This is the first and largest prospective study to date evaluating the combination treatment of mCRPC with these two agents. This trial of radium-223 and abiraterone acetate demonstrates an improvement in Quality of Life, and the synergistic benefits of these agents.


Biography - Neal Shore, MD. FACS

Neal Shore, MD, is an internationally recognized expert in systemic therapies for patients with advanced urologic cancers and innovative therapies to treat patients suffering from prostate enlargement symptoms. Dr. Shore was recently appointed President-Elect of the Large Urology Group Practice Association (LUGPA), which seeks to provide urologists with all the tools they need to effectively care for patients.

Neal D. Shore, MD, FACS, is the Medical Director of the Carolina Urologic Research Center. He practices with Atlantic Urology Clinics in Myrtle Beach, South Carolina. Dr. Shore has conducted more than 100 clinical trials, focusing mainly on prostate and bladder disease.
Dr. Shore is a Certified Physician Investigator who has numerous publications in peer-reviewed journals and has lectured extensively on the treatment of prostate cancer and prostate enlargement. He serves on several industry advisory boards as well as academic and advocacy networks: including the Society Urologic Oncology Clinical Trials Consortium, Bladder Cancer Advocacy Network, Large Urology Group Practice Association, and NCI GU Science Steering Committee. Dr. Shore attended Duke University,’80 and Duke Medical School,’84, Durham, North Carolina. He performed a six-month clinical research fellowship in Pretoria, South Africa, and then completed his General Surgery/Urology training at New York Hospital Cornell Medical Center/Memorial Sloan-Kettering Cancer Center in New York City in 1990. He is the managing partner for Atlantic Urology Clinics, where he has participated in a full-time clinical practice for the past 18 years.